BDPT.US BioAdaptives Inc
- Market cap
- USD 236K
- P/E
- -
- P/B
- 1,520.14x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is BDPT.US undervalued?
Graham numberThe Graham number of BioAdaptives Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BioAdaptives Inc fundamental analysis
No fundamental analysis for BioAdaptives Inc yet.
BioAdaptives Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BioAdaptives Inc
BioAdaptives, Inc. investigates, markets, and distributes natural plant, fungi, and algal-based products and medical devices for humans and animals. The company offers MyndMed for immediate cognitive enhancement, medium-term resilience and memory gains, and long-term neuroprotection and cognitive health; Zeranovia, a weight loss enhancer; Wynovia to help reduce the loss of lean muscle mass during dieting; and Xcellara, a regenerative wellness solution. It also provides canin…
Full company profileBioAdaptives Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BioAdaptives Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 19.0K | 0.00 | 0.00 | 9.93K | 16.3K | 19.8K | 17.2K | 28.6K | 12.7K | 18.3K | 21.0K |
| Gross Profit | 9.39K | 0.00 | 0.00 | 4.89K | 6.10K | 10.1K | 7.13K | 10.8K | 4.03K | 12.5K | 16.7K |
| Operating Income | -171K | -64.4K | -658K | -234K | -254K | -636K | -422K | -229K | -602K | -1.04M | -791K |
| EBITDA | -171K | -63.9K | -658K | -234K | -74.5K | -644K | -544K | -521K | -582K | -1.48M | -435K |
| Net Income | -171K | -62.5K | -1.41M | -438K | -1.08M | -1.05M | -896K | -712K | -899K | -1.56M | 78.0K |
| EPS | -1.84 | -0.65 | -12 | -3.52 | -7.93 | -4.67 | -1.27 | -0.12 | -0.11 | -0.15 | 0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 147K | 3.56K | 110K | 24.2K | 18.8K | 149K | 37.3K | 104K | 262K | 226K | 78.8K |
| Total Liabilities | 323K | 58.00 | 804K | 864K | 1.40M | 1.24M | 1.49M | 1.75M | 1.73M | 2.36M | 1.84M |
| Shareholders' Equity | -176K | 3.51K | -694K | -840K | -1.38M | -1.09M | -1.45M | -1.65M | -1.46M | -2.13M | -1.77M |
| Cash & Short-term Investments | 11.3K | 3.56K | 60.2K | 13.1K | 5.03K | 83.1K | 25.4K | 60.8K | 137K | 158K | 29.2K |
| Total Debt | - | - | 87.8K | 370K | 483K | 437K | 392K | 329K | 343K | 384K | 523K |
| Cash Flow | |||||||||||
| Operating Cash Flow | 5.57K | -540.00 | -402K | -168K | -107K | -159K | -227K | -224K | -250K | -516K | 53.2K |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 3.00 | 18.0K | 0.00 |
| Free Cash Flow | 5.57K | -540.00 | -402K | -168K | -107K | -159K | -227K | -224K | -250K | -534K | 53.2K |
| Ratios | |||||||||||
| ROE | - | -1,783.1% | - | - | - | - | - | - | - | - | - |
| ROA | -116.9% | -1,754.1% | -1,278.1% | -1,810.0% | -5,717.8% | -706.7% | -2,401.2% | -684.6% | -343.3% | -689.6% | 99.0% |
| Net Profit Margin | -899.7% | - | - | -4,411.6% | -6,599.9% | -5,309.5% | -5,216.6% | -2,492.6% | -7,096.1% | -8,523.4% | 371.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BioAdaptives Inc dividends
BioAdaptives Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 2:1 on Jan 23, 2025.
Who owns BioAdaptives Inc
- Insiders 0.15%
- Institutions 0.00%
- Public & others 99.85%
- Shares outstanding 197M
- Free float 194M
BioAdaptives Inc company profile
- Company name
- BioAdaptives Inc
- Ticker
- BDPT.US
- Exchange
- USA Stocks
- Sector
- Consumer Defensive
- Industry
- Food Products
- Employees
- 1
- Fiscal year end
- December
- Address
- 2620 Regatta Drive, Las Vegas, NV, United States, 89128
- Phone
- 702 659 8829
- Website
- shopbioadaptives.com
About BioAdaptives Inc
BioAdaptives, Inc. investigates, markets, and distributes natural plant, fungi, and algal-based products and medical devices for humans and animals. The company offers MyndMed for immediate cognitive enhancement, medium-term resilience and memory gains, and long-term neuroprotection and cognitive health; Zeranovia, a weight loss enhancer; Wynovia to help reduce the loss of lean muscle mass during dieting; and Xcellara, a regenerative wellness solution. It also provides canine products under the PawPa brand; dog chew products under the Regen brand; and Lung Flute, a medical device. The company was formerly known as APEX 8 Inc. and changed its name to BioAdaptives, Inc. in September 2013. BioAdaptives, Inc. was incorporated in 2013 and is based in Las Vegas, Nevada.
BioAdaptives Inc management
1- Mr. James E. KeenerCEO & Chairman · born 1971